bioMérieux S.A. (OTCMKTS:BMXMF – Get Free Report) hit a new 52-week high during trading on Wednesday . The stock traded as high as $122.52 and last traded at $122.52, with a volume of 0 shares traded. The stock had previously closed at $122.52.
Analyst Ratings Changes
Separately, UBS Group upgraded shares of bioMérieux to a “strong-buy” rating in a research report on Thursday, August 22nd.
Get Our Latest Analysis on BMXMF
bioMérieux Stock Performance
About bioMérieux
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.
Featured Stories
- Five stocks we like better than bioMérieux
- Basic Materials Stocks Investing
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- With Risk Tolerance, One Size Does Not Fit All
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for bioMérieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMérieux and related companies with MarketBeat.com's FREE daily email newsletter.
